Siemens Healthineers Atellica CI Analyzer compact testing system

The latest addition to the Siemens Healthineers Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer for immunoassay and clinical chemistry testing, has received FDA clearance and is now available in many of the world’s major markets. Labs operating at low to medium testing volumes will benefit from good turnaround time predictability, advanced reporting functionality, and focused safety and security measures.

Every lab, regardless of size, needs to tackle challenges resulting from labour shortages — from producing test results to enable predictable care, to protecting staff, securing data and reaching environmental goals. The analyser makes it possible for both standalone labs and satellite labs of wider health networks to have the same reagents, consumables and intelligent software as the company’s flagship Atellica Solution — now condensed into a 1.9 m² footprint that’s suitable for smaller laboratories.

The next-generation laboratory analyser anticipates workflow bottlenecks, mitigates them proactively, and delivers insights based on data that help staff do their job effectively and efficiently. Preservation of space in the lab, staff allocation per analyser, turnaround time and usage of reagents are all addressed.

The analyser is engineered with differentiating capabilities to leverage downtime and increase lab efficiency and profitability. Random access sampling, micro-volume aspiration, and automatic maintenance and quality control scheduling enable labs to deliver more predictable sample turnaround times. Chemistry and immunoassay engines run independently so throughput is not compromised if one of the two needs to stop.

The product comes equipped with the Atellica Laboratory Evaluation Suite to deliver inspection-ready reports. This helps labs meet accreditation guidelines without the need for additional software and enables staff to refocus their time on other critical lab operations. User authentication, role-based authorisations and audit trails are available for increased security.

With a planned menu of more than 200 assays across 20 disease states, each lab in a health network can choose the best tests for its patient population to keep pace with demand and satisfy clinical needs of patients that may otherwise go unmet. More than 50 key assays can deliver results in under 14 min.